ArticleJAMA network open2020
Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
Article in JAMA network open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 568 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
568 citing papers in PubMed, 3 syntheses or guidelines pooled it, 926 citations in OpenAlex.
- Evaluating the effectiveness of substance use disorder treatment centers: a systematic review of international standards and outcomes.Substance abuse treatment, prevention, and policy · 2026Pooled it
- The comparative effects of prenatal exposure to methadone versus buprenorphine for opioid use disorder on neonatal outcomes: a systematic review and meta-analysis.BMC pregnancy and childbirth · 2026Pooled it
- Recommendations for managing adults with chronic non-cancer pain in primary care: A systematic clinical guideline review.Journal of evaluation in clinical practice · 2025Pooled it
- Strategies to increase attendance in substance use disorder group treatment: results from a randomized controlled trial.Harm reduction journal · 2026Trial
- Does perceived stigma impact opioid use disorder treatment uptake? A cross-sectional secondary analysis of buprenorphine engagement among syringe service program participants.Addiction science & clinical practice · 2026Trial
- Comparing two strategies to support the implementation of evidence-based practices for substance use disorders in VA's permanent supportive housing program: a protocol for a type 3 hybrid cluster-randomized controlled trial.Implementation science : IS · 2026Trial
- Implementation of mobile medical units for naloxone distribution and MOUD linkage in Ohio's HEALing Communities Study: a community case study.Frontiers in public health · 2026Trial
- Project BETTER: Outcomes at the pregnancy-to-postpartum transition from a pilot clinical trial of a technology-delivered intervention for birthing people receiving medication for opioid use disorder.Families, systems & health : the journal of collaborative family healthcare · 2025Trial
- Implementation of contingency management with women engaging in polysubstance use.Addiction science & clinical practice · 2025Trial
- Barriers and facilitators to scaling up medications for opioid use disorder in Kentucky: qualitative perspectives of treatment organization staff.Substance abuse treatment, prevention, and policy · 2025Trial
- Validation of Medicaid claim-based opioid treatment program retention quality measures.Journal of substance use and addiction treatment · 2026Article
- Continuity of Medications for Opioid Use Disorder in States With and Without Medicaid Prescription Cap Policies.Medical care · 2026Article
- How do services offered within opioid treatment programs vary based on state methadone policies?Journal of substance use and addiction treatment · 2026Article
- Exploring the addictive potential of α-methylfentanyl and acetyl-α-methylfentanyl in animal models.Psychopharmacology · 2026Article
- Would we, could we? Measuring attitudinal and capacity barriers to supporting recovery housing residents on medication for opioid use disorder.Journal of substance use and addiction treatment · 2026Article
- Association Between Integrated Treatment Services and Access to Detoxification and MOUD Across US Treatment Facilities.The journal of behavioral health services & research · 2026Article
- Adiposity and inflammation mediate altered metabolic profile in individuals with opioid use disorder.Journal of psychiatric research · 2026Article
- Trends in Buprenorphine and Methadone Dispensing Among Medicare Advantage and Commercial Enrollees, 2019-2024.AJPM focus · 2026Article
- Racial and Ethnic Disparities in Buprenorphine and Naloxone among Medicaid Beneficiaries after Emergency Department Visits and Hospitalizations.Journal of general internal medicine · 2026Article
- Brixadi for Stimulant Use Disorder: Evolving Pharmacologic Considerations and Clinical Implications.Advances in therapy · 2026Review
508 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Importance: Although clinical trials demonstrate the superior effectiveness of medication for opioid use disorder (MOUD) compared with nonpharmacologic treatment, national data on the comparative effectiveness of real-world treatment pathways are lacking. Objective: To examine associations between opioid use disorder (OUD) treatment pathways and overdose and opioid-related acute care use as proxies for OUD recurrence. Design, Setting, and Participants: This retrospective comparative effectiveness research study assessed deidentified claims from the OptumLabs Data Warehouse from individuals aged 16 years or older with OUD and commercial or Medicare Advantage coverage. Opioid use disorder was identified based on 1 or more inpatient or 2 or more outpatient claims for OUD diagnosis codes within 3 months of each other; 1 or more claims for OUD plus diagnosis codes for opioid-related overdose, injection-related infection, or inpatient detoxification or residential services; or MOUD claims between January 1, 2015, and September 30, 2017. Data analysis was performed from April 1, 2018, to June 30, 2019. Exposures: One of 6 mutually exclusive treatment pathways, including (1) no treatment, (2) inpatient detoxification or residential services, (3) intensive behavioral health, (4) buprenorphine or methadone, (5) naltrexone, and (6) nonintensive behavioral health. Main Outcomes and Measures: Opioid-related overdose or serious acute care use during 3 and 12 months after initial treatment. Results: A total of 40 885 individuals with OUD (mean [SD] age, 47.73 [17.25] years; 22 172 [54.2%] male; 30 332 [74.2%] white) were identified. For OUD treatment, 24 258 (59.3%) received nonintensive behavioral health, 6455 (15.8%) received inpatient detoxification or residential services, 5123 (12.5%) received MOUD treatment with buprenorphine or methadone, 1970 (4.8%) received intensive behavioral health, and 963 (2.4%) received MOUD treatment with naltrexone. During 3-month follow-up, 707 participants (1.7%) experienced an overdose, and 773 (1.9%) had serious opioid-related acute care use. Only treatment with buprenorphine or methadone was associated with a reduced risk of overdose during 3-month (adjusted hazard ratio [AHR], 0.24; 95% CI, 0.14-0.41) and 12-month (AHR, 0.41; 95% CI, 0.31-0.55) follow-up. Treatment with buprenorphine or methadone was also associated with reduction in serious opioid-related acute care use during 3-month (AHR, 0.68; 95% CI, 0.47-0.99) and 12-month (AHR, 0.74; 95% CI, 0.58-0.95) follow-up. Conclusions and Relevance: Treatment with buprenorphine or methadone was associated with reductions in overdose and serious opioid-related acute care use compared with other treatments. Strategies to address the underuse of MOUD are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.